Author Archives: Natalie Themm
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
Company launches Precise™ Tumor test, part of a comprehensive suite combining germline, tumor and companion diagnostics in one easy-to-access solution
Pfizer Completes Acquisition of Arena Pharmaceuticals
Acquisition offers new, differentiated, and potentially best-in-class approach to address needs of a broader number of patients with immuno-inflammatory diseases
PolarityTE Announces $5.0 Million Registered Direct Offering
PolarityTE Announces $5.0 Million Registered Direct Offering
Senate HELP Committee Advances PREVENTS Pandemic Act
The Senate HELP Committee on Tuesday voted 20-2 to advance legislation, the PREVENTS Pandemic Act.
Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program
Co-Diagnostics announced that its Board of Directors has authorized a share repurchase program that would allow the Company to repurchase up to $30 million of CODX common stock.
Tillis, Coons, Cotton, Hirono, and Scott Introduce Bipartisan Bill to Prevent the Chinese Communist Party from Stealing American Intellectual Property
Legislation would combat corrupt Chinese Courts from issuing “anti-suit injunctions” that prevent companies from challenging patent infringement from Chinese companies in American courts.
Xenter Selects New Headquarters in Draper
Xenter has leased 30,000 square feet to accommodate explosive growth in the new Irvine Office Park in Draper, Utah.
Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform
myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health, and will expand testing services across all Renalytix healthcare provider partners
IONIQ Sciences announces IP acquisition and License buyout
IONIQ Sciences announced that it has acquired from OT Acceptance, LLC certain intellectual property formerly licensed to the Company by OT Acceptance.
Metastatic Tumor Treatment with Novel GPX Embolic Device
Innovative Embolic Device by Fluidx Medical Used Successfully in a Variety of Complex Cancer Cases
Known Medicine Partners with Duke University to Predict Lung Cancer Response to Drug Treatments
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Halia Therapeutics New Leadership Team
Halia Therapeutics New Leadership Team
